Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)
China · Delayed Price · Currency is CNY 22.44
+0.22 (0.99%)
Apr 28, 2026, 3:04 PM CST
SHE:002262 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 5,975 | 5,876 | 5,638 | 4,976 | 4,255 | 3,919 |
Other Revenue | 35.12 | 35.12 | 59.61 | 65.63 | 43.49 | 16.53 |
| 6,011 | 5,911 | 5,698 | 5,042 | 4,299 | 3,936 | |
Revenue Growth (YoY) | 2.73% | 3.75% | 13.01% | 17.29% | 9.22% | 17.09% |
Cost of Revenue | 1,763 | 1,678 | 1,546 | 1,403 | 1,037 | 932.68 |
Gross Profit | 4,247 | 4,233 | 4,152 | 3,638 | 3,262 | 3,003 |
Selling, General & Admin | 2,405 | 2,378 | 2,244 | 1,944 | 1,847 | 1,743 |
Research & Development | 650.32 | 685.54 | 595.65 | 549.32 | 454.25 | 351.73 |
Other Operating Expenses | 67.23 | 65.21 | 65.77 | 60.2 | 57.46 | 54.04 |
Operating Expenses | 3,129 | 3,138 | 2,939 | 2,569 | 2,360 | 2,156 |
Operating Income | 1,118 | 1,095 | 1,213 | 1,070 | 901.63 | 847.28 |
Interest Expense | -2.19 | -2.44 | -4.03 | -4.16 | -4.95 | -5.06 |
Interest & Investment Income | 77.15 | 82.62 | 87.82 | 74.85 | 61.8 | 53.92 |
Currency Exchange Gain (Loss) | -1.04 | -1.04 | 0.17 | 0.41 | 0.91 | -1.14 |
Other Non Operating Income (Expenses) | 0.56 | -1.15 | -1.78 | -0.74 | -3.19 | -1.62 |
EBT Excluding Unusual Items | 1,193 | 1,173 | 1,295 | 1,140 | 956.2 | 893.38 |
Gain (Loss) on Sale of Assets | 0.16 | 0.17 | 0.29 | 0.15 | 0.37 | -0.24 |
Asset Writedown | -0.95 | -0.84 | 0.07 | 0.22 | -0.28 | -0.74 |
Other Unusual Items | 0.4 | 0.4 | 0.99 | 28.32 | 33.62 | 23.38 |
Pretax Income | 1,192 | 1,173 | 1,297 | 1,169 | 989.91 | 915.78 |
Income Tax Expense | 120.61 | 118.18 | 155.9 | 134.4 | 109.82 | 117.75 |
Earnings From Continuing Operations | 1,072 | 1,055 | 1,141 | 1,034 | 880.09 | 798.02 |
Minority Interest in Earnings | 2.18 | 2.43 | 2.77 | 2.67 | 20.62 | -0.24 |
Net Income | 1,074 | 1,057 | 1,144 | 1,037 | 900.71 | 797.78 |
Net Income to Common | 1,074 | 1,057 | 1,144 | 1,037 | 900.71 | 797.78 |
Net Income Growth | -8.90% | -7.54% | 10.29% | 15.12% | 12.90% | 9.46% |
Shares Outstanding (Basic) | 1,012 | 1,007 | 1,012 | 1,007 | 1,012 | 1,010 |
Shares Outstanding (Diluted) | 1,012 | 1,007 | 1,012 | 1,007 | 1,012 | 1,010 |
Shares Change (YoY) | 0.48% | -0.50% | 0.53% | -0.53% | 0.22% | -0.24% |
EPS (Basic) | 1.06 | 1.05 | 1.13 | 1.03 | 0.89 | 0.79 |
EPS (Diluted) | 1.06 | 1.05 | 1.13 | 1.03 | 0.89 | 0.79 |
EPS Growth | -9.34% | -7.08% | 9.71% | 15.73% | 12.66% | 9.72% |
Free Cash Flow | 472.28 | 640.98 | 466.07 | 634.31 | 533.27 | 495.01 |
Free Cash Flow Per Share | 0.47 | 0.64 | 0.46 | 0.63 | 0.53 | 0.49 |
Dividend Per Share | 0.400 | 0.400 | 0.360 | 0.320 | 0.200 | 0.200 |
Dividend Growth | 11.11% | 11.11% | 12.50% | 60.00% | - | 100.00% |
Gross Margin | 70.66% | 71.61% | 72.87% | 72.17% | 75.88% | 76.30% |
Operating Margin | 18.61% | 18.53% | 21.29% | 21.22% | 20.97% | 21.53% |
Profit Margin | 17.87% | 17.89% | 20.07% | 20.57% | 20.95% | 20.27% |
Free Cash Flow Margin | 7.86% | 10.84% | 8.18% | 12.58% | 12.41% | 12.58% |
EBITDA | 1,292 | 1,265 | 1,365 | 1,205 | 1,025 | 959.57 |
EBITDA Margin | 21.50% | 21.39% | 23.95% | 23.90% | 23.84% | 24.38% |
D&A For EBITDA | 173.63 | 169.19 | 151.44 | 135.14 | 123.12 | 112.28 |
EBIT | 1,118 | 1,095 | 1,213 | 1,070 | 901.63 | 847.28 |
EBIT Margin | 18.61% | 18.53% | 21.29% | 21.22% | 20.97% | 21.53% |
Effective Tax Rate | 10.11% | 10.07% | 12.02% | 11.50% | 11.09% | 12.86% |
Revenue as Reported | 6,011 | 5,911 | 5,698 | 5,042 | 4,299 | 3,936 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.